Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levmetamfetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 1.00 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methamphetamine SCHEMBL15094315 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42178 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL20211416 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL17008774 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL42615 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL4781849 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL13747483 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL23035463 | 0.98 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL9114797 | 0.98 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| Methamphetamine SCHEMBL11415206 | 0.98 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 960 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260108531-A1 | Methods of Treating Hypogonadism with Transnasal Testosterone Bio-adhesive Gel Formulations in Males with Allergic Rhinitis and Methods for Preventing an Allergic Rhinitis Event | ACERUS BIOPHARMA INC (CA) | 2026-04-23 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-116655475-B | Preparation method of fluoxetine hydrochloride | 山东轩鸿生物医药有限公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240350491-A1 | METHODS AND COMPOSITIONS FOR IMMUNE CONTROL THROUGH DICKKOPF-1 | BAYLOR COLLEGE OF MEDICINE | 2024-10-24 | — | — | US | claimed |
| CN-112368300-B | SPNS2 neutralizing antibodies | 帝人制药株式会社 | 2024-10-01 | — | — | CN | claimed |
| US-20240316063-A1 | METHODS OF TREATING HYPOGONADISM WITH TRANSNASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS IN MALE WITH ALLERGIC RHINITIS, AND METHODS FOR PREVENTING AN ALLERGIC RHINITIS EVENT | ACERUS BIOPHARMA INC (CA) | 2024-09-26 | — | — | US | claimed |
| EP-4398990-A1 | METHODS AND COMPOSITIONS FOR IMMUNE CONTROL THROUGH DICKKOPF-1 | Baylor College of Medicine (US) | 2024-07-17 | — | — | EP | claimed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| US-20010051158-A1 | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | BIOVENTURES, LLC | 2001-12-13 | — | — | US | claimed |
| WO-2001089476-A1 | CHEWING GUMS, LOZENGES, CANDIES, TABLETS, LIQUIDS, AND SPRAYS FOR EFFICIENT DELIVERY OF MEDICATIONS AND DIETARY SUPPLEMENTS | NPD LLC (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001081424-A1 | MONOCLONAL ANTIBODY ANTAGONISTS FOR TREATING MEDICAL PROBLEMS ASSOCIATED WITH D-AMPHETAMINE-LIKE DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2001-11-01 | — | — | WO | claimed |
| US-5847216-A | Preparation of selegiline | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-12-08 | — | — | US | claimed |
| EP-0344675-B2 | Method for the production of selegiline hydrochloride | FARMAK A S (CS) | 1998-11-11 | — | — | EP | claimed |
| EP-0772584-B1 | PROCESS FOR PREPARING SELEGILIN | KNOLL AG (DE) | 1998-06-17 | — | — | EP | claimed |
| EP-0371253-B1 | Method and reagents for detecting amphetamine and/or d-methamphetamine in biological samples | ABBOTT LAB (US) | 1995-09-13 | — | — | EP | claimed |
| US-5262333-A | Fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1993-11-16 | — | — | US | claimed |
| EP-0371253-A2 | Method and reagents for detecting amphetamine and/or d-methamphetamine in biological samples | ABBOTT LABORATORIES (US) | 1990-06-06 | — | — | EP | claimed |
| EP-0344675-A2 | Method for the production of selegiline hydrochloride | FARMAKON (CS) | 1989-12-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | SLC6A4 1194/4885SIGMAR1 3110/4885TAAR1 2972/4885 |
| US-20260108531-A1 | Methods of Treating Hypogonadism with Transnasal Testosterone Bio-adhesive Gel Formulations in Males with Allergic Rhinitis and Methods for Preventing an Allergic Rhinitis Event | SHBG, AR, CYP17A1 | SLC6A4 535/4885SIGMAR1 1107/4885TAAR1 199/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | SLC6A4 1194/4885SIGMAR1 3110/4885TAAR1 2972/4885 |
| US-20010051158-A1 | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | PNMT, EPHA5, EPHB1 | SLC6A4 441/4885SIGMAR1 52/4885TAAR1 106/4885 |
| US-20240316063-A1 | METHODS OF TREATING HYPOGONADISM WITH TRANSNASAL TESTOSTERONE BIO-ADHESIVE GEL FORMULATIONS IN MALE WITH ALLERGIC RHINITIS, AND METHODS FOR PREVENTING AN ALLERGIC RHINITIS EVENT | SHBG, NR5A1, CYP17A1 | SLC6A4 2262/4885SIGMAR1 3215/4885TAAR1 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.